10-QPeriod: Q1 FY2003

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 2003

Filed May 15, 2003For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. reported its first quarter 2003 financial results, showcasing significant revenue growth driven by a new collaboration with Novartis Pharma AG for the development and commercialization of the Interleukin-1 Cytokine Trap (IL-1 Trap). This partnership provided a substantial upfront payment and equity investment from Novartis, bolstering Regeneron's cash position. Despite the positive revenue development and strong cash reserves, the company continued to incur net losses, with R&D expenses increasing due to advancing clinical trial activities, particularly for AXOKINE and the IL-1 Trap. While AXOKINE showed statistically significant, albeit modest, weight loss in Phase III trials, the development of antibodies in a majority of patients presents a challenge. Regeneron is actively engaging with the FDA to determine the future development path for AXOKINE. The company maintains a robust pipeline with other candidates like VEGF Trap and IL-4/13 Trap in clinical development and is exploring strategic collaborations to fuel its research and development efforts. Overall, Regeneron is navigating the high-risk, high-reward landscape of biopharmaceutical development. The Novartis deal injects significant capital and validates the potential of their IL-1 Trap, providing a near-term financial boost. However, the ongoing R&D investments and the inherent uncertainties in drug development mean that profitability remains a longer-term prospect, with careful monitoring of clinical trial progress and strategic partnerships being key for investors.

Key Highlights

  • 1Revenue increased significantly to $10.1 million in Q1 2003 from $4.9 million in Q1 2002, largely due to a $27 million upfront payment and $48 million equity investment from Novartis for the IL-1 Trap collaboration.
  • 2Net loss for the quarter was $30.1 million ($0.68 per share), an increase from $25.4 million ($0.58 per share) in the prior year's quarter, driven by higher R&D expenses.
  • 3Cash and cash equivalents grew substantially to $191.6 million as of March 31, 2003, up from $80.1 million at December 31, 2002, due to the Novartis transaction and strong investing activities.
  • 4Research and Development expenses rose to $34.4 million from $25.5 million year-over-year, reflecting increased investment in clinical programs like AXOKINE and IL-1 Trap.
  • 5AXOKINE Phase III trial showed statistically significant but modest average weight loss (6.2 lbs vs. 2.6 lbs for placebo), with antibody development in two-thirds of patients limiting efficacy.
  • 6The company is discussing AXOKINE data with the FDA to determine future development plans.
  • 7Regeneron maintains a strong cash position and believes existing resources are sufficient to meet operating needs through at least the end of 2004, supported by strategic collaborations.

Frequently Asked Questions

The significant increase in revenue to $10.1 million from $4.9 million in Q1 2002 was primarily driven by a $27.0 million upfront payment and a $48.0 million equity investment from Novartis Pharma AG related to their collaboration agreement for the development and commercialization of the Interleukin-1 Cytokine Trap (IL-1 Trap).

Regeneron reported statistically significant but modest weight loss in its Phase III trial for AXOKINE. A key challenge is the development of antibodies against AXOKINE in approximately two-thirds of treated patients, which appears to limit its efficacy. The company is discussing these trial results with the FDA to determine the future development plan for AXOKINE.

The collaboration with Novartis has significantly strengthened Regeneron's financial position. It provided substantial upfront cash and equity, leading to a considerable increase in cash and cash equivalents to $191.6 million by the end of Q1 2003. This deal also diversifies revenue streams and brings a significant partner for the development and commercialization of the IL-1 Trap.

Regeneron reported a net loss of $30.1 million in Q1 2003, with R&D expenses increasing. However, the company has a strong cash position and believes its resources are sufficient to fund operations through at least the end of 2004. Key expenditures will continue to be directed towards the preclinical and clinical development of product candidates, manufacturing facility expansion, basic research, and technology platform development.